heart failure glp-1 Impact of receptor agonists on cardiovascular outcomes in with preserved ejection fraction (HFpEF): systematic review and meta-analysis | Clinical Research in Cardiology Heart Failure: GLP-1 Drugs Help

A strong detoxification process ensures that harmful substances dont accumulate in the body, promoting better organ function, especially the liver, and reducing the risk of diseases associated with toxin buildup

Normal distribution of data was assessed using histograms, qq-plots and Shapiro Wilk tests for normality

Talk to a licensed healthcare provider before starting, stopping, or changing any treatment

However, the SGLT2i treated cohort were less likely to develop heart failure (RR 0.44 [95% CI 0.23, 0.83] p =0.0092), CKD (RR 0.49 [95% CI 0.28, 0.86] p =0.0118) and be hospitalised for any cause (RR 0.59 [95% CI 0.46, 0.76] p 0.0001) when compared with the GLP-1 RA treated cohort

Rapid improvement in glucose control (e.g